Taken together, these findings suggest that MARCH2 functions as an upstream regulator of TGF-β signaling by modulating the ubiquitination-mediated catalytic activity of the TGF-β type I receptor, thereby driving the expression of TGF-β target genes in various human cancers. Here, TGFB1 is linked to cancer.